BIOSKETCH

Aymeric Audfray a soutenu sa thèse de biochimie le 8 décembre 2008 à l’Université de Limoges sur le thème des fucosylgycannes impliqués dans la myogenèse, en collaboration avec l’INRA. Il a ensuite fait 4 année de post-doc au CERMAV, à Grenoble dans l’équipe d’Anne Imberty (« Glycobiologie Moléculaire ») dans le domaine des interactions protéines/sucres et l’ingénierie des protéines pour des applications médicales. Les principaux projets de recherche concernaient la découverte et la caractérisation de nouvelles lectines (protéines qui reconnaissent les oligosaccharides) ainsi que la création de nouvelles propriétés (stabilité, structure, spécificités,…) pour plusieurs lectines afin de générer des outils biotechnologiques. Au cours de ces activités, il a pu se familiariser avec les techniques de biologie moléculaires (clonage, production de protéines recombinante, mutagenèse,…), les techniques d’analyse des interactions biomoléculaires tels que la microcalorimétrie (ITC,DSC) ou la résonnance plasmonique de surface mais également les techniques de biologie structurale comme la cristallographie des protéines. Plusieurs lectines découvertes et produites de façon recombinante sont aujourd’hui en cours d’évaluation pour des applications en cancérologie. En Décembre 2014, il a rejoint Malvern Panalytical comme ingénieur d’application sur les techniques de microcalorimétrie (ITC et DSC) mais également sur des techniques de caractérisation des protéines comme le suivi individuel des nanoparticules (NTA) ou la dispersion de Taylor (TD). Au sein de la division Bioscience de Malvern Panalytical, Il assure aujourd’hui les essais sur les différents systèmes analytiques ainsi que le support applicatif pour les utilisateurs des solutions Malvern Panalytical.

Alain Baniel has been working in the nutrition research and food industry for more than 25 years. After a PhD in Food Sciences from the University of Nantes, France and a postdoc from Guelph University in Canada, he joined the Nestlé’s subsidiary Proteika as Scientific Director for 10 years. In 2007 he created and managed for 4 years a company specialised in the development and distribution of micronutrition for clinical and sport nutrition.

He is currently the R&D Manager at Ingredia Group. He is responsible for the implementation and coordination of a global research program that develops and investigates a portfolio of milk ingredients for the food and nutrition industries in relation to their functional and health benefits. Among different research programs, he takes a particular interest in the understanding of the digestion behaviours of proteins and its impacts to develop appropriate formula for specific nutritional needs.

Dr Frédéric Baudouin has a PhD in Food Science and Technology obtained at the university Montpellier Supagro in 2012. He performed his PhD on gluten protein extraction and characterisation in partnership with Tereos company. After his PhD, he has worked at Teagasc research centre (Ireland) on the development of protein-enriched cereal snacks for the elderly consumers. He has then worked with the university of Leeds and Goldenfry Company (UK) on fat reduction and quality improvement of instant gravies. He has joined IMPROVE in 2018 and is in charge of the characterisation of plant protein functionality.

François Becher has been working in the bioanalysis and mass spectrometry field at Novartis Basel (Switzerland) and at CEA Saclay, where he has focused his work since 2004 on quantitative approaches for high sensitivity and multiplex analysis of proteins (biomarkers, biopharmaceuticals, toxins) in biological matrices. He contributed to more than 45 publications in international journals in the field of analytical chemistry and mass spectrometry

• since 2004: researcher at CEA Saclay (DRF/IJ/SPI/LEMM)
• 2002-2004: Laboratory head at Novartis Pharma, Basel, Switzerland

• 2013: Habilitation to conduct researches (French university diploma)
• 2002: PhD thesis in Analytical Chemistry (mass spectrometry quantification)
• 1999: Pharm.D thesis

Valérie Belle obtained her PhD in 1995 at the University of Grenoble followed by a postdoctoral stay at the University of Würzburg (Germany), working on methodological aspects of functional and perfusion Magnetic Resonance Imaging. In 1998, she obtained an assistant professor position in Aix-Marseille University and joined the laboratory of Bioenergetics and Protein Engineering. She is now professor at Aix-Marseille University and teaches general physics to B. Sc. and M. Sc. students. In the last few years she focused her research activities on the study of protein dynamics using Site Directed Spin Labeling combined with Electron Paramagnetic Resonance (SDSL-EPR) spectroscopy. She is interested in characterizing structural transitions within proteins mostly arising from protein-protein interaction, in particular in the family of intrinsically disordered proteins. She is also involved in the development of new paramagnetic spin labels aiming at enlarging the potentialities of SDSL-EPR.

Sylvio is the Scientific programs coordinator at Adebiotech, the Paris-based transdisciplinary biotechnology independent think tank. Starting with an academic background in cellular immunology, he gained confirmed >20 years experience in Bioproduction and Purification of therapeutic proteins (and gene therapy vectors). He acquired strong technical and strategic business development experience in various scientific domains (chromatography, cell culture, molecular biology, high-end instrumentation, proteomics, analytical services) through management positions at PALL Life Sciences, Ciphergen Biosystems, Life Technologies, Merck/VWR, BioSepra/Sepracor Inc

Before joining Adebiotech he acted as a strategy consultant for international biotech organizations . Sylvio is a multicultural person and has been a frequent speaker and moderator at various academic and industrial BioProcessing related conferences worldwide.

Adeline Boire is a research scientist at INRA Institute (BIA Unit, Nantes). She is an engineer in Agricultural Science and holds a PhD in physical chemistry of proteins. She is investigating the structure and dynamics of plant proteins assembly in relation to their function in real systems such as food matrices and plant seeds. She is working on plant protein purification using biochemical approaches, on their phase behavior using micro-/millifluidics and on their structural properties using spectroscopy and scattering technics (fluorescence, CD, SAXS, DLS).

Denis Chéreau holds a Ph.D. in microbiology obtained at INRA in Dijon in 1986, on the production of single-cell protein by solid state fermentation. He participated in the creation of Lyven SA specialized in the production and marketing of enzymes obtained by solid state fermentation for fruit juices, bread-making and animal feed markets. He then worked in the starch industry as technical manager in France and the USA and became plant management for 9 years in 2 Tereos wheat and corn plants in Picardy and Alsace. He is currently general manager of IMPROVE SAS first R&D centre dedicated to plant proteins valorisation. IMPROVE started its operational activity end of 2014, employing already 23 scientists and technicians. IMPROVE is contracting with companies working in the food, feed, cosmetic or agrobiobased chemistry in or outside Europe.

Benoit Cudennec, 39, is a doctor in Marine Biotechnology and Physiology from the National Museum of Natural History since 2009. His research activities during his doctorate and post-doctorate at UMR BOREA (CNRS-7208, IRD-207, UPMC, MNHN) concerned, among others, certain biological activities of peptides contained in protein hydrolysates from fishery by-products. Since 2011 he is Associate Professor at Lille University, where he teaches biochemistry. Its research activities take place at the “Institut Régional de Recherche en Agroalimentaire et Biotechnologie Charles Viollette” where he develops, in particular, a multidisciplinary research theme which concerns the study of the mechanisms that potentiate the physiological actions of peptides generated during the gastrointestinal digestion of agro-food proteins.

Eurofins BioPharma Product Testing

Dr Gautier Decock joined Eurofins on 1^st February 2012 and is the Managing Director of Eurofins BioPharma Product Testing in France and Belgium. Gautier has more than 20 years of experience in method development, method validation and quality control for Pharma, Biopharma, Medical Device and Cosmetic Product Testing in chemistry, biochemistry and microbiology.

Graduated from a French “Grande Ecole” in chemistry (INSA), Gautier pursued with his academic studies with a Master of Science in pharmaceutical engineering and industrial technology at the University of Leuven in Belgium and a Ph D in analytical chemistry in inclusion characterization of aroma compounds in cyclodextrins at the University of Lille in France.

Arnaud Delobel is the R&D Director at Quality Assistance. He graduated from ECPM Strasbourg and specialised in mass spectrometry of proteins and peptides during his PhD at the CNRS in Gif-sur-Yvette (France). After a post-doc in Liège (Belgium) focused on proteomics, he joined Quality Assistance in 2006, and held several positions in the company to eventually become R&D Director in 2016.

As the head of the R&D Department, he is responsible for supervising internal R&D projects, aiming at implementing new analytical technologies that will ultimately be provided by Quality Assistance to their customers. He is also supervising the work of Scientific Managers who identify market needs with input from the Management, Regulatory Affairs Manager and external experts, and from any relevant data gathered by Quality Assistance, and that are responsible for interpreting and translating this intelligence into developing new R&D services.

After his post-docs at GSK Biologicals (Rixensart) and at the EMBL (European Molecular Biology Laboratory, Heidelberg), Guy de Martynoff has worked as a Scientific and Operational Manager for more than 25 years in the Biopharmaceutical industry (Chief Operational Officer, Executive Vice President, Scientific Director, Head of Manufacturing, etc.).

Guy has been involved in every domain of the biomanufacturing process: from the Molecular Biology, the protein production and purification process development, up to the QC and preparation of documents for the regulatory agencies (IND, IMPD).

During his professional pathway, he has been directly involved in the development of more than 200 recombinant proteins: viral proteins for diagnostic or vaccines, therapeutic enzymes, transcription factors, hormones, cytokines and many antibodies.

Since 2009, Guy is Chief technology Officer at Cytune Pharma, involved in the biomanufacturing development of RLI-15, a fusion protein linking Interleukin-15 to the binding domain of its α receptor. During these 10 years, the RLI-15 program was a splendid opportunity to manage a project from its academic environment up to the GMP manufacturing of the first clinical batches (named now SO-C101 after the full acquisition of Cytune Pharma by the Czech Group PPF). With its sister company Sotio, Cytune is now developing a vast platform of immunocytokines merging blockbuster antibodies to this RLI-15 pharmaceutical candidate.

Cursus universitaire :

• 1976 Diplôme Universitaire de Technologie (DUT) Option Industrie Alimentaire IUT Créteil •1980 Diplôme d’Ingénieur Génie Biologique Université de Technologie de Compiègne (U.T.C.)
• 1981 DEA (UTC), microbiologie, technologie enzymatique, bioconversion.
• 1984 Diplôme de Docteur Ingénieur (U.T.C.)
• 1994 Habilitation à Diriger des Recherches en Sciences Naturelles ( USTL)

Parcours professionnel :

• 1984-1986: Ingénieur de recherche, UTC- GRADIENT
• 1986-1989: Assistant associé en GIA, IUT A Lille1
• 1989-1995 : Maître de conférences en GIA, IUT A Lille1
• 1995-2011 : Professeur en GIA, IUT A Lille1
• 2008-2013 : Directeur Laboratoire ProBioGEM (EA 1026)

Activités de recherche, programme et encadrement :

L’objectif de ces recherches est de développer dans le laboratoire une recherche en bioprocédé basée sur des approches micro-cinétique et macro-cinétique. La micro-cinétique permettra d’étudier le comportement des catalyseurs biologiques (enzymes, bactéries ou cellules) lors de leurs mises en œuvre en bioréacteurs. Cette approche permettra de concevoir de nouveaux bioprocédés et de modéliser les termes de réactions. Dans le cadre de la macro-cinétique on pourra s’intéresser à l’optimisation et à la maîtrise des bioprocédés qui sont toujours fort complexes, même si par moment ils semblent bien simples. Ainsi les concepts d’intensification de procédé amènent-ils à imaginer des couplages d’opérations originaux ou des modes opératoires nouveaux, où les transferts de quantité de mouvement sont associés aux transferts de matière, les bioréactions associées à des techniques séparatives pour améliorer la productivité et la sélectivité. Notre action porte plus spécifiquement sur le couplage de procédés bio catalytiques et à des techniques séparatives à membrane, avec l’objectif de développer une recherche amont sur le concept de couplage de procédés en étudiant spécifiquement : L’amélioration de la productivité et de la sélectivité d’obtention de peptides à activités ou propriétés physico-chimiques définies par couplage de procédés séparatifs à des bioréacteurs (réacteurs enzymatiques et fermenteurs à membranes). En ce qui concerne le couplage de réacteurs enzymatiques à des techniques séparatives nous cherchons à développer le concept de membrane contacteur en extraction liquide- liquide et d’électro-ultrafiltration à la séparation sélective des peptides. Nous cherchons d’autre part à développer un bioréacteur à membrane pour la production de lipopeptides (surfactine) par Bacillus subtilis : Modification qualitative et quantitative de la production de bio molécules par couplage d’une extraction continue à une fermentation à haute densité cellulaire. Ces recherches s’inscrivent dans le champ plus large de la valorisation de sources de protéines alimentaires (cruor porcin, concentré protéique de luzerne) par hydrolyse enzymatique contrôlée en réacteur à membrane : Conception, mise en œuvre, optimisation de procédés d’obtention d’hydrolysats peptidiques parfaitement définis à l’échelle pilote de 100 litres. Mise en évidence de propriétés d’usage des hydrolysats.

Production scientifique et encadrement

• 50 articles dans des journaux internationaux à comité de lecture, 62 communications orales et par affiches, nationales et internationales.
• Directions et codirections de thèse : 16

Head of Protein Sciences & Technology / Deputy Head Biologics Research Vitry, Sanofi
avril 2015 - Aujourd’hui - Vitry sur Seine

Head of Biologics Generation Department (Acting), Sanofi
décembre 2014 - Aujourd’hui - Vitry sur Seine

Head of Protein Biotherapeutics I- Key interface contact for the interface Biotherapeutics - DSAR, sanofi-aventis
mars 2012 - Aujourd’hui - global

Head of Protein Biotherapeutics I - Global interface between the Biotherapeutics and Drug Safety and Animal Research
Head of Protein Biotherapeutics, sanofi, 2000 - Aujourd’hui - Vitry/France

Expression and purification/characterization of recombinant proteins and antibodies, Biologics, for Medicinal Chemistry and Biotherapeutics projects for all kind of uses (screening, crystallography, IHC, PK-PD, in vitro and in vivo studies...)

Head of protein production Vitry, sanofi aventis, 2000 – 2010 (10 ans)
Expression and purification of recombinant proteins and antibodies, Biologics, for Medicinal Chemistry and Biotherapeutics projects for all kind of uses (screening, crystallography, IHC, PK-PD, in vitro and in vivo studies...)

Group Leader in Biotechnology, Hoechst Marion Roussel, 1988 – 2000 (12 ans)
Purification of proteins. From mg scale to several grams. Support to Medicinal Chemistry projects, and development of purification processes for Biologics.

PhD, MBA, Business Development Manager

Following his PhD in Targeted proteomics at Lyon University in Jérôme Lemoine’s team, Quentin joined Sciex (Danaher) a LC-MS provider. He was part of the EMEA application team dedicated to Omics applications. He developed a strong expertise in global protein analysis and strong background in customers care and relationship.

He joined ANAQUANT in 2016 as Business Development Manager to bring his LC-MS expertise but also his market knowledge on protein analysis and customer needs in Europe. Since 2017, he is an MBA graduate from IAE Lyon.

Dr. Christophe FLAHAUT has a Ph. D degree in Biochemistry of the University of Sciences and Technology Lille 1 (2001). Since 2003, he is Associate Professor in Biochemistry at the University of Artois, in the north of France. He is lecturer in Licence (Biochemistry and Biology) and Master degrees where he teaches the enzymology, the protein purification and characterization technologies, the metabolisms (i) of fatty acids, (ii) nucleic acids, (iii) amino acids, the applied bio-informatics and the biochemistry of foods and mass spectrometry. He is responsible of a professional Licence entitled "Biotechnology and engineering process applied to drinks".

His research activities were dedicated during 10 years to the proteomic approach of the Blood-Brain Barrier (BBB) where he has been responsible of the setting-up of a proteomics plate-form (spot picker, digester, LC-MS/MS, biomarker discovery robot and associated software) based on a MALDI-TOF/TOF mass spectrometer (Bruker Daltonics). Since September 2013, he works in quality and safety of foods within the agro-food and biotechnology research institute named institute Charles VIOLLETTE where he had participated to the setting-up of two mass spectrometers (Synapt G2S, from Waters and Autoflexspeed from Bruker Daltonics) on the REALCAT platform. His main research activity is dedicated to develop concepts and mass spectrometry-based tools to manage the quality and safety of foods (e.g. the identification and characterization of peptides and of microorganisms by ESI-MS/MS and MALDI-TOF mass spectrometry). He is author of 28 scientific papers, 5 reviews, 3 chapters of book and more than 43 oral communications. He is the principal contributor of two declarations of invention.

Yannis FRANÇOIS obtained his PhD in Analytical Chemistry from Pierre and Marie Curie University in 2006 under the direction of Prof. Dr. P. Gareil and Prof. A. Varenne. During his PhD, he gained expertise in capillary electrophoresis by developing methods involving ionic liquids as new separation media. Then he did an posdoctoral fellowship at Paris Descartes University under the supervision of Prof. Mr Gardes-Albert on the characterization by mass spectrometry of proteins stressed by radiation. In 2007, he was appointed associate professor at the University of Strasbourg in the Laboratory of Mass Spectrometry of Interactions and Systems headed by Dr. Emmanuelle LEIZE-WAGNER. He develops new methodologies in CE-ESI-MS and CE-MALDI-MS for structural characterization at different levels of therapeutic proteins.

Chemist by training, Frederic obtained a PhD in Biophysical Chemistry at the University of Orleans in 2000 (Centre de Biophysique Moleculaire, CNRS). He pursued his interest in Structural Biology of viral RNA systems applying NMR as core methodology, starting in 2001 at the Umeå University (Sweden) and continuing a year later at the Radboud University Nijmegen (The Netherlands). In 2004, Frederic started transitioning from Academia to Industry and founded Spinnovation Analytical (Nijmegen, The Netherlands). The company was established as a service organization dedicated to delivering advanced Analytical R&D to the BioPharma. In 2014, Spinnovation operation was moved to the former R&D site of MSD (Oss, The Netherlands) and received GMP certification from the Dutch Health authorities to support Quality Control and GMP release testing activities. At that time, the Dutch group Sinensis Life Sciences acquired majority shares in Spinnovation. A year later, the group Sinensis was acquired by Eurofins who finalized the full acquisition of Spinnovation in 2017. Spinnovation established itself within Eurofins as a center of excellence for NMR, Solid-State Characterization and Cell Media Analysis. Frederic Girard is currently appointed Managing Director of Eurofins Spinnovation Analytical (Oss, The Netherlands).

Dr. Emeric Gueneau is Biacore Application Specialist at GE Healthcare. He studied chemical engineering at National Higher Institute of Chemical Industries (ENSIC). After graduation, he received his Ph.D. in structural biology from the University of Paris Saclay (France) in 2011, working on structure-functions relationships for DNA repair proteins. At GE he is focusing on application and methodology development for new and existing Biacore users. He also has over the past years given supports within academia and industry to expand the application of label-free interaction analysis throughout drug discovery, development and manufacturing processes. He has more than 10 years of experience in label-free technology and on a regular basis, Emeric lectures at conferences and pharma/biotech industry sites and Universities.

Bruno GUIGLIARELLI, is Professor in Physics at Aix-Marseille University, heading the group of “Biophysics of Metalloproteins” in the Laboratory of Bioenergetics and Protein Engineering (BIP-UMR7281). After studies in chemical-physics at ENS Cachan, he obtained his PhD in molecular spectroscopy from the University of Aix-Marseille I in 1986, and his HDR in 1990. With his group, he develops for several years the applications of Electron Paramagnetic Resonance (EPR) to the structural and functional studies of complex enzymes and proteins. His research activity concerns mainly oxidoreductases involved in the energy metabolisms of prokaryotes and their applications in health or bioenergy (hydrogenases, molybdo-enzymes). He has a longstanding expertise in the study of electronic, magnetic and structural properties of metal clusters, radical chemistry, catalytic mechanisms, electron and proton transfers, and protein-protein interactions. His multidisciplinary approach combine the use of advanced EPR techniques, electrochemistry, kinetics studies, theoretical modelling, with other physico-chemical approaches. He notably developed the biostructural applications of spin-labeling combined with EPR to investigate the dynamic properties and structural transitions in proteins and enzymes, and their role in physiological functions. He has authored >150 publications (~5000 citations), 3 books, and supervised 12 PhD theses. He has been previously President of the French EPR Society (ARPE) and President of the French group of Magnetism and Magnetic Resonances (MRM-SCF/SFP), and he currently manages the Aix-Marseille EPR platform which is especially devoted to applications in Biology and Chemistry in the French EPR network.

Dr. Constanze Helbig is a working as Postdoctoral Scientist at Coriolis Pharma, a science-driven contract research organization located in Munich, Germany, for formulation development, lyophilization, and analytics of biopharmaceuticals. She ia a biophysicist by training and received her PhD from the Medical Department of the University of Munich. At Coriolis Pharma, she is responsible for the scientific evaluation and implementation of novel methods and strategies for particle analysis in biopharmaceuticals.

PhD in Molecular Biology at University of Montpellier II.

PostDoc at the University of Groningen, Netherlands

Gilles graduated in Chemistry Engineering (ENSCL) in 2005 and in Business Management (INSEAD MBA) in 2014.

Over the last 12 years he worked through several position in sales, business development and management, both in leading and emerging chromatography companies. Since 2019, he joined PharmaFluidics to support business development in Southern Europe.

Romdhane Karoui is currently working as a Professor at Artois University, France. He is the Responsible of: i) Charles Viollette Institute at Artois-site; and ii) Master of Science entitled “Innovation and Industrial Transfer in Agro-alimentary”. He received his PhD in Food Science from Blaise Pascal University, and the accreditation to supervise research from Polytechnic National Institute of Toulouse, both in France. Following the results that he obtained between 2001 and 2006 by using rapid analytical techniques, he conducted between 2007 and 2009 an industry focused project aiming to design, develop and industrialize a miniaturized system based on fluorescence spectroscopy for on-line measurements of the quality and safety of food products. The project has been recognized by the French Ministry of Higher Education and Research, and between 2009 and 2010 he was engaged as senior research scientist at Gembloux Agro-Bio Tech, Belgium.

The research interests are centered on the use of rapid analytical techniques, specifically near infrared, mid infrared and fluorescence spectroscopy for the determination of the quality and safety of food products. He is the author of more than 90 peer-reviewed scientific papers and more than 100 articles in conference proceedings, book chapters, and reviews. In addition, he serves as both editor and editorial board member for several peer reviewed journals. 

Celine LESUR has been working for Ingredia, leader in functional milk ingredients, since 2004. She is a world expert in this area.

During these 15 years, she developed in particular a new process to produce cheese without whey separation and without fresh milk based on very specific dairy proteins.

With Ingredia, she has delivered 2 patents for this innovative process (Semi Hard Cheese in 2009 and Pasta Filata in 2014).

She is currently the Protein Function Manager. She participates in research programs to investigate, understand and develop new uses for milk proteins for nutritional and food industries.

Alessandro Masiero studied at the University of Padua, where he obtained his master degree in Medicinal Chemistry and Pharmaceutical Technology and his PhD degree in Biochemistry and Biophysics. During his Master and PhD theses, he began learning computational structural biology and molecular dynamics simulations, and he worked on Von Hippel Lindau syndrome and circadian rhythm entrainment.

After obtaining his PhD degree, he began as a postdoc at Sanofi France, getting then hired as a research scientist in bioinformatics and computational protein engineering of biotherapeutics.

Dr. Tim Menzen is Chief Technology Officer at Coriolis Pharma, a science-driven contract research organization located in Munich, Germany for formulation development, lyophilization, and analytics of biopharmaceuticals, and responsible for new technologies and innovation. He is a pharmacist by training and received his PhD in the group of Prof. Dr. Wolfgang Frieß at the LMU in Munich, Germany. Tim is current Community Leader of the AAPS Biopharmaceutical Product Attributes and Biological Consequences (PABC) Community.

Marcin Moczulski obtained his Master’s degree in Biotechnology from the University of Life Science of Poznan in 1999.

Previously as Product Manager at Comesa Polska Sp. z o.o. responsible for sales and application support of Beckman Coulter Life Science products, he is working for SCIEX since 5 years.

He has over 19 years’ experience in Biotechnology and Capillary Electrophoresis. Skilled in Sales, Support and conducting Trainings.

Marcin Moczulski is currently the Senior Filed Applications Specialist for SCIEX CE & BioPharna EMEA.

Dr. Christophe Quétard is a Field Application Scientist (FAS) at FortéBio.

Prior to joining Pall FortéBio (now FortéBio - Biologics by Molecular Devices), Dr. Quétard worked as a FAS for Biacore AB, later GE Healthcare Life Sciences, from 1999 to 2013 where he developed an expertise in label-free interaction analysis technologies including Surface Plasmon resonance (SPR), Isothermal Titration Calorimetry (ITC) and Differential Scanning Calorimetry (DSC). Later, he moved to ProteinSimple (now Bio-Techne) where, as a FAS, he looked after Simple Western, Imaged Capillary Electrophoresis (iCE) and Micro Flow Imaging (MFI) users.

Dr. Quétard received his Ph.D. degree in Biochemistry from the University of Orléans, France in 1998.

Alexey Rak got his M.Sc in Biology and Genetics, and in Biochemistry. He then completed PhDs in Biochemistry and Biophysics working on protein biosynthesis machinery characterization. He did his PostDoc and then held a Group Leader position at Max-Planck Institute for Molecular Physiology in Germany working in the field of vesicular membrane trafficking. For this work he was awarded several honors including European Young Investigator Award in 2004. Since 2007 Alexey joined Sanofi as head of protein crystallization in Paris where he has developed new methods to characterize biophysical properties of proteins including biologics, and enabling the lead discovery of challenging protein targets. Since 2014 he is heading Bio Structure and Biophysics at Integrated Drug Discovery in Sanofi.

After an MSc in biochemistry at the UPS (Toulouse), Bertrand Raynal has completed his PhD and post-doct in the Wellcome Trust Centre for Cell-Matrix Research in Manchester where he has developed skills in biophysic more specifically in hydrodynamic. Since 2007, he is an experimental officer in the molecular scale biophysical core facility in Institut Pasteur (PFBMI) where he is in charge of the hydrodynamic characterization (AUC, SLS, DLS, DPI, SAXS). In 2017, Bertrand Raynal has initiated the quality control of purified proteins service of the Institut Pasteur that run more than 300 sample a year.

Alain Riaublanc was first graduated as engineer from the Ales School of Mines and then he obtained a PhD in Food Science at Agrosup Montpellier. He was recruited in 1993 at the INRA center in Nantes to work on the physicochemistry of emulsified systems. Subsequently he expanded his area of activity to foams and gels with a focus on the functional properties of protein assemblies in these systems. In recent years, its proteins of interest evolve from the animal domain towards plant sources.

Since 2013, he is leader of the team « interfaces and dispersed systems » of the BIA unit.

Audrey Romelard has been working in analytical Research and Development for 12 years. She graduated from Engineering school “Polytech Lille”, training GB IAAL. She first worked for Genoscreen, before joining Ingredia's team in 2007 as Development and Analytical Specialist.

Following studies in molecular biology and biochemistry at the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland, Dr. Roesli performed his PhD thesis in the lab of Prof. Dario Neri at the same university. After the subsequent PostDoc period, he led his own research group on biomarker identification and development of antibody-based therapeutics at the German Cancer Research Center in Heidelberg, Germany. Finally, he moved to industry where he is working in the analytical development and characterization of both biosimilars and new biological entities, with a focus on quality by design and the assessment of critical quality attributes.

She has started in 1999 in Rhône-Poulenc Rorer and put in place the analytical characterization of recombinant proteins. She has started working with microfluidics-based automated electrophoresis in 2001. Then, she has joined the purification team to increase her competences in purification. She’s now head of Protein Analysis and Developability team in Biologics Research department in Sanofi.

Daniel Some, PhD, Principal Scientist, Wyatt Technology

Dr. Daniel Some develops scientific and technical content on new applications utilizing Wyatt’s instrumentation. He collaborates with instrument users and manages internal projects. He is involved in developing Wyatt’s instrumentation for characterization of biomolecular interactions. Dr. Some obtained his B.Sc. from the Israel Institute of Technology and Ph.D. from Brown University, both in Physics, and completed his postdoctoral research at Los Alamos National Laboratory and the Weizmann Institute of Science.

Pierre Soule defended a PhD in biophysics from the University Pierre & Marie Curie on single molecule microscopy and force measurement. From it, he joined NanoTemper Technologies GmbH as an application specialist where he developed a strong knowledge on affinity measurement and protein stability. Through his position he strengthened his knowledge in both physic and biology while providing customer support on many users across Europe and since recently exclusively in France.